Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping resistant tumors: could radiation keep breast cancer therapy working longer?

NCT ID NCT06925984

Disease control Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether giving precise radiation (SBRT) to a few growing cancer spots can help women with ER+/HER2- metastatic breast cancer stay on their current hormone therapy or CDK4/6 inhibitor longer. The study enrolls 48 women whose cancer has started to progress in 1 to 3 places after at least 6 months on treatment. They will continue their systemic therapy while receiving SBRT to those resistant spots, with the goal of delaying the need to switch to a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this approach could help women with metastatic breast cancer stay on their current well-tolerated treatment longer before needing to switch to a new one.
What could go wrong
This is a small early-phase study with only 48 participants, so results may not apply to everyone. The treatment only targets a few resistant spots, and the cancer may still progress elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ECOG performance status 0-2. * Histologically confirmed ER+/HER2- MBC. * History of polymetastatic disease. Patients with genuine oligometastatic disease and 1-3 oligoprogressive lesions are only allowed if ablative therapy of all metastases is deemed impossible. * Under 1st to 2nd systemic treatment line with hormonotherapy and/or CDK4/6 inhibitors for at least 6 months before progression. * Progressive disease at 1-3 extracranial sites. * Ability to treat all progressive lesions locally according to the treating radiation oncologist. Exclusion Criteria: * Second malignancy if it is not in complete remission. * Previous local treatment for oligoprogression under the current systemic treatment line * Current progression in a lesion that has been treated with SBRT before and is not amendable for surgery or radiofrequency ablation (RFA). * Progressive or newly diagnosed brain metastases. Known brain metastases that have been nonprogressive for at least 6 months, are not an exclusion criterion. * Inability to continue the same ST line after local therapy (for example because of toxicity or patient refusal). * Pregnancy. * Inability to sign the informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER+, HER2-, metastatic breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast neoplasm estrogen-receptor positive breast cancer metastatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Oligoprogressive metastatic disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Groeninge

    RECRUITING

    Kortrijk, Belgium

  • AZ Sint-Maarten

    RECRUITING

    Mechelen, Belgium

  • CHU UCL Namur - Site Saint Elisabeth

    RECRUITING

    Namur, Belgium

  • Jules Bordet Institute

    RECRUITING

    Brussels, Belgium

  • UZ Gent

    RECRUITING

    Ghent, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.